Anzeige
Mehr »
Login
Mittwoch, 12.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
Milliardär und "Starinvestor" verdoppelt jetzt seine Position in einem Pennystock
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJVC ISIN: KYG4403H1002 Ticker-Symbol: 6XY 
Frankfurt
12.05.21
09:16 Uhr
0,970 Euro
-0,015
-1,52 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
HBM HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
HBM HOLDINGS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,9801,04018:31

Aktuelle News zur HBM HOLDINGS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE IB/IIA CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN AUSTRALIA-
HBM HOLDINGS Aktie jetzt für 0€ handeln
28.04.HBM HOLDINGS-B (02142): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING-
28.04.HBM HOLDINGS-B (02142): NOTICE OF ANNUAL GENERAL MEETING-
28.04.HBM HOLDINGS-B (02142): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING-
26.04.HBM HOLDINGS-B (02142): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
26.04.HBM HOLDINGS-B (02142): RESIGNATION OF DIRECTOR1
20.04.HBM HOLDINGS-B (02142): ANNUAL REPORT 20201
31.03.Harbour BioMed revenue jumps 160% for FY2020-
29.03.HBM HOLDINGS-B (02142): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 20201
22.03.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE I CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN CHINA1
11.03.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN TANFANERCEPT (HBM9036) PHASE III CLINICAL TRIAL-
10.03.HBM HOLDINGS-B (02142): DATE OF BOARD MEETING-
26.02.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED APPROVAL OF THE INVESTIGATIONAL NEW DRUG APPLICATION FOR COMBINATION THERAPY OF HBM4003, A NEXT-GENERATION, ...-
02.02.HBM HOLDINGS-B (02142): INSIDE INFORMATION - UPDATE ON BATOCLIMAB (HBM9161)1
02.02.XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 02.02.2021389The following instruments on XETRA do have their first trading 02.02.2021 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 02.02.2021 Aktien 1 US1914592050 Cochlear Ltd. 2...
► Artikel lesen
28.01.HBM HOLDINGS-B (02142): TRADING HALT-
28.01.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE GRANT OF BREAKTHROUGH THERAPY DESIGNATION TO BATOCLIMAB (HBM9161) BY CHINA CENTER FOR DRUG EVALUATION-
19.01.Credit Suisse starts HBM Holdings at HK$151
17.12.20Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange304CAMBRIDGE, Mass. and SUZHOU, China, Dec. 17, 2020 /PRNewswire/ -- HBM Holdings Limited ("Harbour BioMed", "HBM" or the "Company"; Stock Code: 02142.HK), a global clinical-stage biopharmaceutical...
► Artikel lesen
09.12.20HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering128This press release is NOT for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and...
► Artikel lesen
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1